Delmar pharmaceuticals, inc. (DMPI)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10
Cash flows from operating activities
Loss for the year

-

-

-7,662

-

-

-

-10,463

-11,138

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss for the period

-

-

-

-

-

-

-

-

-

-

-

-

8,792

9,520

8,195

8,864

-5,533

-6,479

-4,452

-4,347

-3,823

-4,935

-3,449

-8,727

-15,940

-20,147

-21,016

-14,226

-7,413

-11

-19

-18

-24

-25

-29

-33

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities
Amortization of intangible assets

11

11

12

16

20

24

25

24

22

20

18

16

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of intangible assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2

4

6

8

8

8

8

0

0

0

-

-

-

-

-

-

-

-

-

-

Change in fair value of derivative liability

-

-

-

433

3

5

3

60

245

165

528

245

-1,340

-986

-2,027

-2,341

136

-921

650

627

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrants issued for services

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of derivative liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-8,633

-14,665

-15,609

0

0

0

-

-

-

-

-

-

-

-

-

-

Change in fair value of derivative liability due change in warrant terms

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

295

270

263

165

-23

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Shares issued for services

15

15

14

13

0

0

0

-

-

-

0

564

630

630

710

146

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Performance stock unit expense

-

-

-

526

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrants issued for services

-

-

-

-

-

-

-

192

0

0

0

-

-

-

691

647

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Shares issued to Valent for royalty reduction

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

598

0

0

0

-

-

-

-

-

-

-

-

-

-

Non-cash derivative issue costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-2,201

0

0

0

-

-

-

-

-

-

-

-

-

-

Units issued for services

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

-

-

-

-

-

-

-

-

-

-

Warrants issued for patents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

Warrants issued for services

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

15

124

124

124

0

0

0

-

-

-

-

-

-

-

-

-

-

Stock option expense

377

381

344

426

420

458

563

495

448

461

157

124

361

235

386

394

2

41

177

186

596

1,154

1,283

1,519

2,493

2,146

0

0

0

-

-

-

-

-

-

-

-

-

-

Prototype drug product

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

Net income (loss) after adjustments of non-cash items

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-4,089

-3,979

-3,796

-3,630

-3,726

-4,536

0

0

0

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities
Prepaid expenses and deposits

-125

-183

-607

-754

-832

-834

-385

-173

953

1,010

1,039

1,063

34

-36

-4

-100

-163

11

19

10

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest, taxes and other receivables

1

20

59

-13

-52

-14

-28

-37

-8

6

2

58

38

1

2

-7

-16

2

16

16

38

3

7

-7

-66

-34

0

0

0

-

-

-

-

-

-

-

-

-

-

Prepaid expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

13

186

142

0

0

0

-

-

-

-

-

-

-

-

-

-

Accounts payable and accrued liabilities

-31

-371

153

202

-838

-771

-528

295

1,099

1,313

1,032

598

144

36

33

-178

160

222

78

517

81

116

83

-186

-174

-537

0

0

0

-

-

-

-

-

-

-

-

-

-

Related party payables

182

124

43

164

-9

-245

81

71

52

192

10

45

41

148

37

-47

-14

19

-2

35

7

-71

-175

-181

-260

-338

0

0

0

-

-

-

-

-

-

-

-

-

-

Total changes in non-cash working capital

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-256

-56

483

373

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

Accounts Receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

5

0

0

0

0

-

-

-

Accounts Payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

2

2

2

2

0

-0

0

0

0

Net cash used in operating activities

-7,161

-7,253

-6,508

-6,327

-7,047

-8,395

-9,562

-9,850

0

0

0

-

-

-

-

-

-4,400

-4,423

-4,283

-3,853

0

0

0

-

-

-

-

-

-

-9

-16

-11

-22

-22

-29

-38

0

0

0

Net proceeds from the issuance of units

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

9,639

0

0

0

-

-

-

-

-

-

-

-

-

-

Series A preferred stock dividend

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash flows from operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-4,004

-4,280

-5,520

0

0

0

-

-

-

-

-

-

-

-

-

-

Net cash flows from investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

-

-

-

Cash flows from financing activities
Net proceeds from the issuance of shares and warrants

0

0

0

-

-

-

-

8,945

16,877

16,877

16,877

7,932

0

0

0

2,453

2,453

2,453

2,453

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net proceeds from the exercise of warrants

0

0

0

-

-

-

-

-

-

-

-

545

0

0

0

-

-

-

-

1,404

3,663

3,746

3,008

2,480

221

0

0

0

0

-

-

-

-

-

-

-

-

-

-

Series A preferred stock dividend

8

8

8

8

8

8

8

8

8

8

8

8

8

8

8

8

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

9,982

9,898

10,683

4,074

692

1,089

304

9,249

0

0

0

-

-

-

-

-

2,348

2,438

2,771

847

0

0

0

-

-

-

-

-

-

13

10

7

7

0

0

0

-

-

-

Proceeds of loan from officer

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

Proceeds of loan from officer

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

-

Net proceeds from the issuance of common shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

0

0

-

-

-

Net cash flows from financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

2,480

221

9,639

0

0

0

-

-

-

-

-

-

-

-

-

-

Increase (decrease) in cash and cash equivalents

2,821

2,645

4,175

-2,253

-6,354

-7,318

-9,271

-614

6,406

7,604

8,357

428

1,163

1,460

1,994

4,402

-2,069

-2,001

-1,511

-3,005

-467

-178

-855

-1,523

-4,058

4,119

0

0

0

-

-

-

-

-

-

-

-

-

-

Issuance of preferred shares for the settlement of the loan payable to Valent (note 4)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Reclassification of derivative liability upon the exercise or exchange of Investor Warrants (note 6)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Reclassification of stock option liability upon the forfeiture of stock options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Deferred costs recognized as equity issue costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of shares for the settlement of accounts payable (notes 7 and 10)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

-

-

-

-

-

-

-

-

-

-

Issuance of units for the settlement of accounts payable (notes 8 and 10)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

-

-

-

-

-

-

-

-

-

-

Non-cash share issuance costs (note 9)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

6,288

0

0

0

-

-

-

-

-

-

-

-

-

-

Cashless exercise of Placement Agent Warrants (note 9)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

239

239

239

0

0

0

-

-

-

-

-

-

-

-

-

-

Settlement of accounts payable with a loan payable (note 5)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

-

-

-

-

-

-

-

-

-

-

Exercise of CA$0.50 warrants for no additional consideration (note 7)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

259

259

241

0

0

0

-

-

-

-

-

-

-

-

-

-

Deferred costs (note 9(f))

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

90

0

0

0

-

-

-

-

-

-

-

-

-

-

Effects of exchange rates on cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

-

-

-

Net increase/ (decrease) in cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3

-5

-3

-2

-8

-18

-27

0

0

0

Interest paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

-

-

-

Income Taxes paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

-

-

-